Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
Abroad (travel likely)RecruitingPHASE1
Conditions
Rheumatoid Arthritis · Pemphigus Vulgaris · Granulomatosis With Polyangiitis · Systemic Lupus Erythematosus
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
IRIS Research and Development, LLC, Plantation, Florida, United States
Contact: Principal Investigator (Guillermo J. Valenzuela, M.D.)Azarel Abinader, M.D. (Sub-investigator)
Study leads
Guillermo J. Valenzuela, M.D.
Principal Investigator
IRIS Research and Development, LLC
Kathy I. Perez, M.D.
Study Director
IRIS Research and Development, LLC